Show simple item record

dc.contributor.authorMelaku Gebresillassie, Begashaw
dc.contributor.authorBiruk Gebeyehu, Minaleshewa
dc.contributor.authorMelaku Abegaz, Tadesse
dc.contributor.authorAsfaw Erku, Daniel
dc.contributor.authorBasazn Mekuria, Abebe
dc.contributor.authorDechassa Tadesse, Yokabd
dc.date.accessioned2021-01-11T05:18:43Z
dc.date.available2021-01-11T05:18:43Z
dc.date.issued2016
dc.identifier.issn1179-1373en_US
dc.identifier.doi10.2147/HIV.S103081en_US
dc.identifier.urihttp://hdl.handle.net/10072/400884
dc.description.abstractPURPOSE: Cotrimoxazole preventive therapy (CPT) is a feasible, inexpensive, and well-tolerated way of using cotrimoxazole intervention for patients living with HIV/AIDS to reduce HIV/AIDS-related morbidities and mortalities caused by various bacteria, fungi, and protozoa. The aim of this study was to evaluate the use of cotrimoxazole as a prophylaxis therapy among patients living with HIV/AIDS at Gondar University Referral Hospital (GURH), northwestern Ethiopia. MATERIALS AND METHODS: A retrospective cross-sectional study was used to evaluate the use of cotrimoxazole as a prophylaxis therapy among people living with HIV/AIDS at GURH, northwestern Ethiopia from September 2013 to October 2015. Medical records of 264 patients were selected by using systematic random sampling technique from the sampling frame list of all patients' medical records. Data were collected from patients' medical records using the structured checklist and evaluated against World Health Organization (WHO) guidelines on the use of cotrimoxazole prophylaxis. The quantitative data were analyzed using the statistical packages for social sciences Version 20. Descriptive and binary logistic regression analyses were used to describe and assess the association between different variables. RESULTS: Approximately 95 (36.0%) patients were at WHO clinical stage III at the start of CPT. The use of CPT was consistent with the guidelines in the rationale for indication 200 (75.75%) and dose 263 (99.62%), despite the presence of contraindications in 24 (9.90%) patients. The occurrence of cotrimoxazole-associated side effects was higher in the first month of therapy. Problems regarding drug-drug interactions were identified in 63 (23.86%) patients, and 92 (34.84%) patients discontinued CPT due to different reasons. CONCLUSION: Although the practice of discontinuation of CPT and follow-up for adverse drug effects were not consistent with WHO guidelines on the rational use of cotrimoxazole prophylaxis, the use of CPT among people living with HIV/AIDS at GURH was appropriate. Health professionals who were working in the antiretroviral therapy units should update themselves and adhere to the available updated guidelines to reduce the occurrence of adverse effects and prophylaxis failure.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglishen_US
dc.publisherDove Medical Pressen_US
dc.relation.ispartofpagefrom125en_US
dc.relation.ispartofpageto133en_US
dc.relation.ispartofjournalHIV/AIDS - Research and Palliative Careen_US
dc.relation.ispartofvolume8en_US
dc.subject.fieldofresearchClinical Sciencesen_US
dc.subject.fieldofresearchcode1103en_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsInfectious Diseasesen_US
dc.subject.keywordsdrug use evaluationen_US
dc.subject.keywordscotrimoxazoleen_US
dc.titleEvaluation of cotrimoxazole use as a preventive therapy among patients living with HIV/AIDS in Gondar University Referral Hospital, northwestern Ethiopia: a retrospective cross-sectional studyen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationMelaku Gebresillassie, B; Biruk Gebeyehu, M; Melaku Abegaz, T; Asfaw Erku, D; Basazn Mekuria, A; Dechassa Tadesse, Y, Evaluation of cotrimoxazole use as a preventive therapy among patients living with HIV/AIDS in Gondar University Referral Hospital, northwestern Ethiopia: a retrospective cross-sectional study, HIV/AIDS - Research and Palliative Care, 2016, 8, pp. 125-133en_US
dcterms.licensehttp://creativecommons.org/licenses/by-nc/3.0/en_US
dc.date.updated2021-01-11T05:16:41Z
dc.description.versionVersion of Record (VoR)en_US
gro.rights.copyright© 2016 Gebresillassie et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).en_US
gro.hasfulltextFull Text
gro.griffith.authorErku, Daniel


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record